CURIOX BIOSYSTEMS PTE LTD DropArray Micro plate "Developed by...

CURIOX BIOSYSTEMS PTE LTD

DropArray Micro plate

"Developed by Curiox Biosystems, DropArray is a system comprised of proprietary microplates and washer for lowvolume cell-based assays. It allows scientists to use a fraction of the cells, media and reagents they have traditionally used, and still acquire rich, high content data. Equally effective for adherent and suspension cells, DropArray eliminates evaporation, and is compatible with most automated plate handling and imaging equipment. DropArray Microplates support assays including those requiring long-term incubation and multiple washing steps, even when using suspension or weakly adherent cells. DropArray is perfect for in vitro toxicity assays, and high content screening using scarce or expensive cells, like hepatocytes, lymphocytes and stem cells."

http://www.nature.com/marketplace/2013/04/lab-equipment-2/

HT200 Washing Station
The HT200 Washing Station accepts automatically or manually loaded DropArray™ Microplates into a liquid-tight chamber formed with a clamping mechanism. After an aqueous washing buffer is automatically added, the station gently shakes the microplate to facilitate washing with minimal loss of cells. The station then tilts the microplate, using gravity to drain excess washing buffer from the planar surface, avoiding the harsh, high-velocity liquid exchange associated with traditional washers and microplates. Buffer is added at a very low velocity, preventing cell loss. Despite the low velocity, plate processing time is comparable to traditional washers because the entire plate is treated at once. After the microplate is removed from the station the plate is ready for accepting the next set of reagents

LT210 Washing Station
The LT210 Washing Station accepts manually loaded DropArray™ Microplates into a liquid-tight chamber formed with a clamping mechanism. After an aqueous washing buffer is automatically added, the station gently shakes the microplate to facilitate washing with minimal loss of cells. The station then tilts the microplate, using gravity to drain excess washing buffer from the planar surface, avoiding the harsh, high-velocity liquid exchange associated with traditional washers and microplates. Buffer is added at a very low velocity, preventing cell loss. Despite the low velocity, plate processing time is comparable to traditional washers because the entire plate is treated at once. After the microplate is removed from the station the plate is ready for accepting the next set of reagents.

http://www.curiox.com

ORION SYSTEMS INTEGRATION PTE LTD (Orion is emerging from its gestation to be revenue generating.)
Pheonix Thermal Bonder
Orion’s commercial Thermal Bonder for fine pitch flip chips has been accepted by industry. We are finalising the sale of significant batch orders with the first batch of 6 units aimed to be shipped within the first half of 2014 subject to no delay in customer’s expansion plans. The expanding global demand for hand-held devices and tablet computers
will use fine pitch flip chips as opposed to conventional chips. This is expected to accelerate the process for chip manufacturers to retool into manufacturing and packaging fine pitch flip chips. Fine pitch flip chips are high power computing chips that meet present days’ requirement for small but powerful chips for increased multi-functional computing needs in the industry.

BIOBOT SURGICAL PTE LTD

iSR'obot Mona Lisa is an eight-axis surgical robot with ultrasound imaging, which aids the intelligent planning and execution of transperineal prostate cancer surgery. The intelligent image-guided system enables the cancer-staging location to be pin-pointed within 1.5mm range to increase accuracy in diagnosis for the early treatment of cancer. The precise co- ordinates taken of each biopsy sample allow accurate repeat procedures to be carried out, thus facilitating prostate cancer focus therapy.
The iSR’obot Mona Lisa increases prostate cancer detection rates, enabling earlier prostate cancer detection and reduces post-operative morbidity, saving treatment costs and improves the quality of life for the patient.
Key features:
Early accurate Prostate cancer detection through more accurate and systematic diagnosis
Using real time 3D ultrasound Robotic guided biopsy and maximal coverage of the prostate
Minimal risk of sepsis or haematuria
Ease of patient follow up: with patient data management, abilities to recall previous executed biopsy plan, make remark on specific biopsy location and re-biopsy at exact location
Minimal invasive Focus Therapy enabled
User friendly intuitive interface monitoring and recording

http://www.biobotsurgical.com/product.aspx

IPTEC PTE LTD
iPtec Intellectual Property Translation Engineering Centre Pte Ltd is a Centre of Excellence in the MedTech industry. iPtec fills a gap in the current translational ecosystem, and accelerates the time-to-market for medical devices. iPtec is a multi-disciplinary engineering firm that delivers innovative design solutions to rapid prototyping, and comprehensive product translation services for the medical device industry. This includes in-house regulatory specialists, and clinical engineers to interact with our clinical partners. iPtec has a strong network of Key Opinion Leaders and Expertise partners to further strengthen our translation services.

iPtec, a wholly owned subsidiary, has received a cash grant of S$4.5m from a Singapore government agency responsible for enterprise development in Singapore to set up the medtech IP translation services.The services will involve prototyping, clinical trials, regulatory approvals up to commercialisation rendered to technology start-up companies and research institutions on a commercial basis for profit. The RCA will enable iPtec to cooperate in developing clinically driven innovations with the Singhealth Group on shared IP rights. The partnership will position the Group and the Singhealth Group to render consultative and relevant clinical trial support services to local medtech companies bridging a gap in the eco-system of medical technology.
The Group believes that the partnership is the first of its kind in the world where a public sector health care group cooperates with a private sector medtech IP translation company to render a complete and seamless service to the medtech industry. The Group believes that the partnership will provide a strong platform for the group to develop and grow its medical technology business.

http://www.sysmac.com.sg/ip.html


This are just an overview of the Technology being described as being the “infelction point” of this company.

Financials at the moment are: $21m cash in bank, and a profit of around 7m last year (lost around 2m thanks to exchange)


To conclude an address from the chairman about the progress of these technologies

“In our Annual Report, we pointed out that the Group’s business has hit an inflection point. Your Board recognised that this situation might likely eventuate, about 3 years ago, when it embarked on new technologies as a platform for sustainable growth. We are glad to have recognised the situation earlier as the inflection point has become more apparent in the last financial year.
While innovations and new technologies are the hallmark for businesses to maintain sustainability in growth, gestations and risks are generally higher so are the rewards. As the Group has exercised financial prudence in investing in this segment, the investments have not impacted against the performance of the respective core businesses which continue to generate sustainable revenue and profits.
Gestation for the Group’s new technologies has tapered. These investments have begun commercialisation and are expected to at least break-even in 2014. As we gain more customers acceptance in live runs and, where medical technologies are concerned, progressively secure full regulatory approvals in the countries where we market our products, we expect exponential growth to gain traction. The Group has received financial support from a Singapore enterprise development agency, in recognising our experiences with medical technologies to expand into medtech translation businesses, to encourage us to expand our platform to grow in this segment.”